Research Groups

Research Groups

Immune Deficiency, Cancer Predisposition & Precision Oncology

Assoc.-Prof. Dr. Kaan Boztug (MD) Our group works at the interface of  inborn immune disorders and inherited predisposition to childhood tumors, aiming  to understand fundamental mechanisms of immune surveillance relevant to pediatric oncology and immunotherapy approaches.

Innovative Cancer Models

Dr. Martin Distel (PhD) Our research focus is on the generation of pediatric cancer models in zebrafish to better understand tumor initiation and tumor progression on a cellular and molecular level. In addition, zebrafish disease models are applied in small compound screens to identify therapeutic compounds.

Immunological Diagnostics

Univ.-Doz. Dr. Michael Dworzak (MD) We aim at developing and evaluating new diagnostic, prognostic and therapeutic approaches for paediatric leukaemias using high-end multi-colour flow cytometry.

Clinical Cell Biology and FACS Core Unit

Priv.-Doz. Dr. René Geyeregger (PhD) With our engagement in flow cytometry and GMP-compliant work, we are a supportive interface between research and therapy.

Clinical Genetics

Univ.-Prof. Dr. Oskar A. Haas (MD) Leukaemias are malignant diseases of the haematopoietic system that are caused by genetic defects. Our primary task is to diagnose and in detail characterise these diverse changes which are important for specific treatment and basic research, with the use of molecular and cytogenetic methods.

Integrative Analysis & Developmental Cancer Genomics

Dr. Florian Halbritter (PhD)
We combine "multi-omics" analysis with computational, statistical, and machine learning methods to dissect the molecular framework of pediatric cancers.

Development of Cellular Therapeutics

Univ.-Prof. Dr. Wolfgang Holter (MD) Our group focuses on the development of therapeutic strategies based on T cells modified with chimeric antigen receptors (CARs).

LCH Biology

DDr. Caroline Hutter (MD, PhD) The goal of our laboratory is to better understand the pathobiology of Langerhans Cell Histiocytosis (LCH) in order to develop new treatment approaches to the disease.

Tumour Immunoediting

Dr. Eva Maria König (PhD) We study the role of NK cells in tumor immunoediting and aim to identify the molecular mechanisms of tumor immune evasion.

Molecular Biology of Solid Tumours

Univ.-Prof. Dr. Heinrich Kovar (PhD) To increase therapeutic efficacy while decreasing side effects, we have to specifically target the Achille`s heel of the disease.

Studies & Statistics for Integrated Research and Projects

Univ.-Prof. Dr. Ruth Ladenstein (MD), MBA, cPM Multinational networking is fundamental for clinical research of malignant cancer in children and adolescents. Only controlled large-scale clinical trials allow improving complex treatment strategies, whilst smaller studies allow testing innovative drug medications to further improve survival rates. The clinical trail unit S2IRP undertakes all efforts to serve the complex tasks of clinical trial management.

Molecular Microbiology

Univ.-Prof. DDr. Thomas Lion (MD, PhD), MSc Our group primarily focuses on the improvement of treatment outcomes, particularly in transplant recipients and patients with life-threatening infections, by developing and implementing new diagnostic technologies.

Genetics of Leukaemias

Dr. Sabine Strehl, PhD Tracking down the faulty genes that cause leukamia with the ultimate goal to establish predictive biomarkers for the optimisation of risk-adapted therapy.

Tumour Biology

Dr. Sabine Taschner-Mandl (PhD) We aim to establish, validate and apply new diagnostic and therapeutic tools to facilitate personalised treatment of children with malignant tumours.

Epigenome-based Precision Medicine

Dr. Eleni M. Tomazou, PhD The aim of our group is to establish an epigenome-based precision medicine program for pediatric sarcomas.

Biology of Leukaemias

N.N. We are trying to understand why and how leukemia evolves and use our knowledge to improve treatment and advance cure of affected children.